Pregnancy Testing

Gain insights about the health of your baby during pregnancy

Noninvasive Prenatal Screening

Noninvasive prenatal Screening Tests (NIPT) can screen for trisomy 21 (Down syndrome) and other chromosomal abnormalities—as well as the sex of your baby—as early as nine weeks into your pregnancy, and with a high degree of accuracy.

Labcorp offers flexibility across our NIPT screening options, talk to your doctor about which option may be right for you

 

Understanding Your MaterniT Results

This video explains what your MaterniT results mean and what next steps or other testing you might consider. 

Understanding the difference

NIPT vs. Serum Screening vs. Diagnostic Tests

You may choose to have NIPT, a serum screening test, a diagnostic test, a combination of the tests, or no testing at all. Here are the most important differences between the tests:

  • NIPT


  • Can be performed as early as nine weeks
  • Tells you the chances of your baby having a chromosomal abnormality such as trisomy 21 (Down syndrome) and—depending on the type of NIPT you choose—many more conditions
  • Screens for fetal sex
  • Done via a maternal blood sample from the mother’s arm
  • Does not cause miscarriages
  • Can require diagnostic testing to confirm a positive result (a “positive result” likely means the baby is affected)
  • Serum Screening


  • Can be performed as early as 10 weeks
  • Done via a maternal blood sample from the mother’s arm
  • Does not cause miscarriages
  • Tells you the chance that your baby could have trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and when drawn after 15 weeks, open neural tube defects (such as spina bifida)
  • Sometimes show a high risk even when the baby does not have one of these problems
  • Diagnostic Tests


  • Can be performed as early as 10 weeks (CVS) or 15 weeks (amniocentesis)
  • Tell you with greater than 99% accuracy whether your baby is affected or is not affected with Down syndrome or trisomy 18
  • Tell you with greater than 90% accuracy whether your baby is affected with an open neural tube defect
  • Can test for other genetic disorders when additional risks are identified in a patient’s history
  • Are estimated to cause miscarriage in 1 in 300 to 1 in 500 pregnancies for amniocentesis and up to 1 in 100 with CVS

Additional Resources

Reference

  1. Ob-Gyns release revised recommendations on screening and testing for genetic disorders [news release]. Washington, DC: American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM); March 1, 2016. https://www.acog.org/About-ACOG/News-Room/News-Releases/2016/Ob-Gyns-Rel.... Accessed September 26, 2017.